Direct Healthcare Professional Communication on the recently published epidemiological studies evaluating the risk of birth defects with Zofran® (Ondansetron)

Direct Healthcare Professional Communication on the risk of birth defects from the recently published epidemiological studies for Zofran® (Ondansetron)

Updated information on posology for intravenous use and dose dependant QT interval prolongation.  

Risk of developing abnormal changes in the electrical activity of the heart ​​